Observational studies link the use of GLP−1 receptor agonists to a reduced risk of Alzheimer’s disease, dementia, ischemic stroke, and mortality—by as much as 45% in some studies (140). Here, GLP1R is linked to early-onset autosomal dominant Alzheimer disease.